Fig. 1
From: Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
A Individual patient (n = 11) absolute FCV at baseline and at 12 months post treatment with infliximab. B Individual patient (n = 5) absolute FCV at baseline, 12 and 36-months post treatment with infliximab. C Individual patient (n = 11) absolute FEV1 at baseline and at 12 months post treatment with infliximab. D Individual patient (n = 5) absolute FEV1 at baseline, 12 and 36-months post treatment with infliximab. IFX infliximab; FVC forced vital capacity; M month; L liters